APA (7th ed.) Citation

Hontecillas-Prieto, L., Hontecillas-Prieto, L., Hontecillas-Prieto, L., Hontecillas-Prieto, L., García-Domínguez, D. J., García-Domínguez, D. J., . . . Cruz-Merino, L. d. l. (2024). CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Hontecillas-Prieto, Lourdes, et al. CD8+ NKs as a Potential Biomarker of Complete Response and Survival with Lenalidomide Plus R-GDP in the R2-GDP-GOTEL Trial in Recurrent/refractory Diffuse Large B Cell Lymphoma. Frontiers Media S.A, 2024.

MLA (9th ed.) Citation

Hontecillas-Prieto, Lourdes, et al. CD8+ NKs as a Potential Biomarker of Complete Response and Survival with Lenalidomide Plus R-GDP in the R2-GDP-GOTEL Trial in Recurrent/refractory Diffuse Large B Cell Lymphoma. Frontiers Media S.A, 2024.